Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Hepatitis Delta International Network (HDIN)

doi:10.1016/j.jhep.2018.12.022

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Hepatitis Delta International Network (HDIN)

Internal Medicine Division

Research output: Contribution to journal › Review article › peer-review

131 Scopus citations

Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.

Original language	English
Pages (from-to)	1008-1015
Number of pages	8
Journal	Journal of Hepatology
Volume	70
Issue number	5
DOIs	https://doi.org/10.1016/j.jhep.2018.12.022
State	Published - 1 May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Hepatitis D
New treatment approaches
Surrogate marker
Treatment endpoints

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.jhep.2018.12.022

Cite this

@article{8308f2dbc21547bb863b420e708415a3,

title = "Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy",

abstract = "Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible {\textquotedblleft}trial endpoints{\textquotedblright}) that could be used across different clinical trials.",

keywords = "Hepatitis D, New treatment approaches, Surrogate marker, Treatment endpoints",

author = "\{Hepatitis Delta International Network (HDIN)\} and Cihan Yurdaydin and Zaigham Abbas and Maria Buti and Markus Cornberg and Rafael Esteban and Ohad Etzion and Gane, \{Edward J.\} and Gish, \{Robert G.\} and Glenn, \{Jeffrey S.\} and Saeed Hamid and Theo Heller and Christopher Koh and Pietro Lampertico and Yoav Lurie and Michael Manns and Raymundo Parana and Mario Rizzetto and Stephan Urban and Heiner Wedemeyer and A. Wranke and \{Pinheiro Borzacov\}, \{L. M.\} and C. Lobato and S. Hamid and E. Ceausu and Dalekos, \{G. N.\} and A. Turcanu and Niro, \{G. A.\} and F. Lubna and M. Abbas and P. Ingiliz and P. Ferenci and T. Vanwolleghem and T. Hayden and N. Dashdorj and A. Motoc and S. Hardtke",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2019",

month = may,

day = "1",

doi = "10.1016/j.jhep.2018.12.022",

language = "English",

volume = "70",

pages = "1008--1015",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - Treating chronic hepatitis delta

T2 - The need for surrogate markers of treatment efficacy

AU - Hepatitis Delta International Network (HDIN)

AU - Yurdaydin, Cihan

AU - Abbas, Zaigham

AU - Buti, Maria

AU - Cornberg, Markus

AU - Esteban, Rafael

AU - Etzion, Ohad

AU - Gane, Edward J.

AU - Gish, Robert G.

AU - Glenn, Jeffrey S.

AU - Hamid, Saeed

AU - Heller, Theo

AU - Koh, Christopher

AU - Lampertico, Pietro

AU - Lurie, Yoav

AU - Manns, Michael

AU - Parana, Raymundo

AU - Rizzetto, Mario

AU - Urban, Stephan

AU - Wedemeyer, Heiner

AU - Wranke, A.

AU - Pinheiro Borzacov, L. M.

AU - Lobato, C.

AU - Hamid, S.

AU - Ceausu, E.

AU - Dalekos, G. N.

AU - Turcanu, A.

AU - Niro, G. A.

AU - Lubna, F.

AU - Abbas, M.

AU - Ingiliz, P.

AU - Ferenci, P.

AU - Vanwolleghem, T.

AU - Hayden, T.

AU - Dashdorj, N.

AU - Motoc, A.

AU - Hardtke, S.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.

AB - Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.

KW - Hepatitis D

KW - New treatment approaches

KW - Surrogate marker

KW - Treatment endpoints

UR - https://www.scopus.com/pages/publications/85062155428

U2 - 10.1016/j.jhep.2018.12.022

DO - 10.1016/j.jhep.2018.12.022

M3 - Review article

C2 - 30982526

AN - SCOPUS:85062155428

SN - 0168-8278

VL - 70

SP - 1008

EP - 1015

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 5

ER -

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this